Fannin Partners
Fannin Partners is an early-stage life sciences product development group that advances therapeutic and platform programs across ophthalmology, oncology, immunology, fibrosis, and reproductive health. The company develops Raptamer therapeutics using an in-house discovery platform to generate high-affinity peptidomimetic DNA oligomers and partners with academic and industry collaborators to translate scientific breakthroughs into clinical development.
Leadership & Board
- Current Number of Employees
- 34
- Current LinkedIn Followers
- 4,624
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $300K
- Total Funding Rounds
- 1
- Latest Funding Amount
- $300K
- Latest Funding Round
- Investment
- Post-Money Valuation
- ―
Employee Trend
Fannin Partners had 34 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Fannin Partners had 4,624 followers as of October 12, 2026. The number of followers increased by 10 (0.22%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 09, 2026 | Investment | $300.00K | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| National Eye Institute | Investment |
Similar Companies
A snapshot of private companies similar to Fannin Partners, helping you discover and navigate related company profiles.
Related News and Analysis
